BCMA-targeted CAR-T cells, bb2121 (Ide-cel), which contains a second-generation CAR incorporating an anti-BCMA single-chain variable fragment with 4-1BB co-stimulatory domain and CD3Zeta signaling domain, revealed potent cytotoxicity against MM cells regardless of the ratio of BCMA expression in MM cells or the presence of soluble BCMA [123]. Here, TNFRSF17 is linked to Miyoshi myopathy.